MeSH tree: D02.241.223.100.100.435
Scientists from King's College London have successfully applied a new technology that disarms one of the most potent weapons cancer cells use to weaken the effects of chemotherapy drugs.
Oct 29, 2025
0
19
Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, but survival rates of ...
Sep 25, 2025
0
92
Western Sydney University researchers have led a global team to pioneer a new AI-powered tool to assess the risk of developing type 1 diabetes (T1D) and predict treatment responses, potentially changing how the disease is ...
Jun 6, 2025
0
36
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, as a policy advocate at drugmaker Johnson & Johnson, was to tell patient and physician groups about ...
Dec 31, 2024
0
27
Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent among East Asians that contributes to drug resistance, driving the aggressive growth of cancer cells ...
Nov 7, 2024
0
34
Dermatofibrosarcoma protuberans (DFSP) is a rare skin sarcoma known for its high recurrence rates, making treatment particularly challenging. While surgery remains the standard option, it often leads to scarring and other ...
Oct 22, 2024
0
32
Most employers have little idea what the pharmacy benefit managers they hire do with the money they exchange for the medications used by their employees, according to a KFF survey.
Oct 14, 2024
0
30
A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by researchers.
Oct 7, 2024
0
34
An analysis of 15 name-brand drugs and their "skinny label" generic counterparts found that competition from these counterparts saved Medicare Part D nearly $15 billion from 2015 to 2021. Skinny labeling allows generic drug ...
May 3, 2024
0
61
The U.S. government could save taxpayers between $228 million and $2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban ...
Jun 8, 2023
0
51
